DOP2009000115A - Funciones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada - Google Patents

Funciones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada

Info

Publication number
DOP2009000115A
DOP2009000115A DO2009000115A DO2009000115A DOP2009000115A DO P2009000115 A DOP2009000115 A DO P2009000115A DO 2009000115 A DO2009000115 A DO 2009000115A DO 2009000115 A DO2009000115 A DO 2009000115A DO P2009000115 A DOP2009000115 A DO P2009000115A
Authority
DO
Dominican Republic
Prior art keywords
fgf
functions
biological activity
improved biological
receiver
Prior art date
Application number
DO2009000115A
Other languages
English (en)
Inventor
Francis Blanche
Beatrice Cameron
Mark Nesbit
Celine Nicolazzi
Sylvie Sordello
Marc Trompe
Original Assignee
Centelion
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centelion filed Critical Centelion
Publication of DOP2009000115A publication Critical patent/DOP2009000115A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a funsiones Fc con receptor para FGF soluble, modificadas que comprenden una fusión de un fragmento o dominio solubles de la parte de receptor para FGF (porción que establece el objetivo o fijadora) con una región Fc de una parte de immunoglobulina (porción con función efectora), que tiene actividad biolólica mejorada, que incluye actividades de ADCC/CDC, a composiciones que la contienen, y a métodos de producir dichas moléculas de fusión Fc con receptor para FGF soluble modificadas.
DO2009000115A 2006-11-28 2009-05-19 Funciones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada DOP2009000115A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291824 2006-11-28

Publications (1)

Publication Number Publication Date
DOP2009000115A true DOP2009000115A (es) 2010-02-15

Family

ID=37908084

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2009000115A DOP2009000115A (es) 2006-11-28 2009-05-19 Funciones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada

Country Status (5)

Country Link
CN (1) CN101589145B (es)
DO (1) DOP2009000115A (es)
ES (1) ES2366160T3 (es)
UY (1) UY30749A1 (es)
ZA (1) ZA200903134B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2640406A1 (en) * 2010-11-15 2013-09-25 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins
CN102219860B (zh) * 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
WO2014018673A2 (en) * 2012-07-24 2014-01-30 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US9957313B2 (en) 2013-03-15 2018-05-01 Remegen, Ltd. FGFR-FC fusion proteins and the use thereof
TWI791422B (zh) * 2015-11-23 2023-02-11 美商戊瑞治療有限公司 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6656728B1 (en) * 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion

Also Published As

Publication number Publication date
ZA200903134B (en) 2010-08-25
ES2366160T3 (es) 2011-10-17
CN101589145B (zh) 2013-11-13
UY30749A1 (es) 2008-07-03
CN101589145A (zh) 2009-11-25

Similar Documents

Publication Publication Date Title
NI200900097A (es) FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLÓGICA MEJORADA.
WO2007115837A3 (en) Combination of an anti-edb fibronectin domain antibody/ il2 fusion protein and a further small molecule
WO2008060705A8 (en) Anti-dll4 antibodies and methods using same
CY1121580T1 (el) ΝΕΟΙ ΠΡΟΑΓΩΓΕΙΣ β-ΑΚΤΙΝΗΣ ΚΑΙ RPS21 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
WO2008091798A3 (en) Optimized ca9 antibodies and methods of using the same
WO2009071696A3 (en) Humanized antibody molecules specific for il-31
GB2455449A (en) Activatable binding polypeptides and methods of indentifcation and use thereof
WO2007140505A3 (en) Vaccine carrier
WO2008079995A3 (en) Conjugate of natriuretic peptide and antibody constant region
WO2009112245A9 (en) Antibody against the csf-1 r
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
EP2535351A3 (en) Dual specificity antibody fusions
WO2007130697A3 (en) Anti-ephb4 antibodies and methods using same
WO2006085967A3 (en) OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
NZ592420A (en) Cd86 antagonist multi-target binding proteins
WO2007133290A8 (en) Anti-ox40l antibodies and methods using same
CL2008003784A1 (es) Anticuerpo humanizado anti proteina e2 del virus de la hepatitis c o un fragmento de union; acido nucleico que lo codifica; vector y celula huesped que comprenden dicho acido nucleico; metodo para producir el anticuerpo; composicion farmaceutica que comprende el anticuerpo
DOP2009000115A (es) Funciones fc con receptor para fgf soluble modificadas, con actividad biologica mejorada
WO2008002472A3 (en) Systematic evaluation of sequence and activity relationships using site evaluation libraries for engineering multiple properties
WO2008048519A3 (en) Antibodies that bind cxcr7 epitopes
WO2007127506A3 (en) Anti-ephrinb2 antibodies and methods using same
WO2007120766A3 (en) Erythropoietin receptor agonists
WO2007053570A3 (en) A polypeptide complex of trpm8 and calmodulin and its uses thereof
WO2008030564A3 (en) Aglycosylated antibodies and methods of making and using those antibodies
WO2008110914A3 (en) Methods for producing active scfv antibodies and libraries therefor